[go: up one dir, main page]

AR077564A1 - Inhibidores de quinasa que regulan la senal de apoptosis - Google Patents

Inhibidores de quinasa que regulan la senal de apoptosis

Info

Publication number
AR077564A1
AR077564A1 ARP100102515A ARP100102515A AR077564A1 AR 077564 A1 AR077564 A1 AR 077564A1 AR P100102515 A ARP100102515 A AR P100102515A AR P100102515 A ARP100102515 A AR P100102515A AR 077564 A1 AR077564 A1 AR 077564A1
Authority
AR
Argentina
Prior art keywords
alkyl
halo
cycloalkyl
heterocyclyl
optionally substituted
Prior art date
Application number
ARP100102515A
Other languages
English (en)
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of AR077564A1 publication Critical patent/AR077564A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Los compuestos poseen actividad inhibitoria de la quinasa reguladora de la senal de apoptosis (ASK1) y por lo tanto resultan utiles en el tratamiento de afecciones mediadas por ASK1, que incluyen trastornos autoinmunes, enfermedades inflamatorias, enfermedades cardiovasculares y enfermedades neurodegenerativas. También se refiere a composiciones farmacéuticas que comprenden uno o varios de los compuestos de formula (1), y a métodos para preparar los compuestos de formula (1). Reivindicacion 1: Un compuesto de formula (1) en donde R1 es alquilo C1-10, cicloalquilo C3-8, alquenilo C1-10, alquinilo C1-10, arilo, heteroarilo o heterociclilo, todos los cuales están opcionalmente sustituidos con 1, 2 o 3 sustituyentes seleccionados de halo, oxo, alquilo C1-6, cicloalquilo C3-8, heterociclilo, fenilo, fenoxi, halo, -CN, -O-R6, -C(O)-R6, -OC(O)-R6-C(O)-O-R6, -N(R6)-C(O)-O-R7, -N(R6)-C(O)-R7, -N(R6)-C(O)-N(R6)(R7) y -C(O)-N(R6)(R7), en donde alquilo, cicloalquilo, heterociclilo, fenilo y fenoxi están opcionalmente sustituidos con 1, 2 o 3 sustituyentes seleccionados de alquilo C1-6, cicloalquilo C3-8, alcoxi C1-6, hidroxilo y halo; con la condicion de que R1 no sea metilo cuando R3 es morfolinilo o furilo; en donde R6 y R7 se seleccionan independientemente del grupo que consiste en hidrogeno, alquilo C1-6 o cicloalquilo C3-8; o R6 y R7, cuando se toman junto con el nitrogeno al cual están unidos, forman un heterociclo; R2 es hidrogeno, halo, ciano, alcoxi o alquilo opcionalmente sustituido con halo; R3 es arilo, heteroarilo o heterociclilo, todos los cuales están opcionalmente sustituidos con 1, 2 o 3 sustituyentes seleccionados de alquilo C1-6, alcoxi C1-6, cicloalquilo C3-8, cicloalquilalquilo, arilo, arilalquilo, heteroarilo, heteroarilalquilo, heterociclilo, heterociclilalquilo, halo, haloalcoxi, oxo, -CN, -O-R6, -O-C(O)-R6, -O-C(O)-N(R6)(R7), -S-R6, -N(R6)(R7), - S(=O)-R6, -S(=O)2R6, -S(=O)2-N(R6)(R7), -S(=O)2-O-R6, -N(R6)-C(O)-R7, -N(R6)-C(O)-O-R7, -N(R6)-C(O)-N(R6)(R7), -C(O)-R6, -C(O)-O-R6, -C(O)-N(R6)(R7) y -N(R6)-S(=O)2-R7, en donde el alquilo, alcoxi, cicloalquilo, arilo, heteroarilo o heterociclilo está además opcionalmente sustituido con uno o varios sustituyentes seleccionados de halo, hidroxilo, oxo, -CN y -O-R6; con la condicion de que el resto heteroarilo o heterociclilo incluya al menos un átomo de nitrogeno anular; X1, X2, X3, X4, X5, X6, X7 y X8 son independientemente C(R4) o N, en donde cada R4 es independientemente hidrogeno, hidroxilo, halo, alquilo C1-6, alcoxi C1-6 o cicloalquilo C3-8, en donde el alquilo o cicloalquilo está además opcionalmente sustituido con uno o varios sustituyentes seleccionados de halo, hidroxilo, oxo, -CF3, -O-CF3, -N(R6)(R7), -C(O)-R6, -C(O)-O-R7, -C(O)-N(R6)(R7), -CN, -O-R6; o X5 y X6 o X6 y X7 se unen para proporcionar cicloalquilo fusionado, arilo fusionado o heteroarilo fusionado, todos los cuales están opcionalmente sustituidos con alquilo C1-6, hidroxilo o halo; y con la condicion de que al menos uno de X2, X3 y X4 sea C(R4); al menos dos de X5, X6, X7 y X8 sean C(R4); y al menos uno de X2, X3, X4, X5, X6, X7 y X8 sea N.
ARP100102515A 2009-07-13 2010-07-12 Inhibidores de quinasa que regulan la senal de apoptosis AR077564A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22507909P 2009-07-13 2009-07-13
US22507609P 2009-07-13 2009-07-13
US28926309P 2009-12-22 2009-12-22

Publications (1)

Publication Number Publication Date
AR077564A1 true AR077564A1 (es) 2011-09-07

Family

ID=42670422

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100102515A AR077564A1 (es) 2009-07-13 2010-07-12 Inhibidores de quinasa que regulan la senal de apoptosis

Country Status (27)

Country Link
US (7) US8378108B2 (es)
EP (4) EP3858824A1 (es)
JP (4) JP5745721B2 (es)
KR (3) KR101755524B1 (es)
CN (1) CN102482257B (es)
AR (1) AR077564A1 (es)
AU (1) AU2010273597B2 (es)
BR (1) BR112012000894A2 (es)
CA (1) CA2767894C (es)
CY (1) CY1119889T1 (es)
DK (2) DK2933252T3 (es)
ES (3) ES2662397T3 (es)
HR (2) HRP20150185T1 (es)
HU (1) HUE038529T2 (es)
LT (1) LT2933252T (es)
ME (1) ME02104B (es)
MX (1) MX2012000708A (es)
NO (1) NO2933252T3 (es)
NZ (1) NZ597533A (es)
PL (3) PL2933252T3 (es)
PT (3) PT2454250E (es)
RS (2) RS56981B1 (es)
SI (3) SI3363797T1 (es)
SM (2) SMT201800172T1 (es)
TW (3) TWI598347B (es)
UY (1) UY32786A (es)
WO (1) WO2011008709A1 (es)

Families Citing this family (207)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110092266A (ko) 2008-08-04 2011-08-17 씨에이치디아이 파운데이션, 인코포레이티드 소정 키누레닌-3-모노옥시게나아제 억제제, 약학적 조성물, 및 그의 사용 방법
TWI598347B (zh) * 2009-07-13 2017-09-11 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
WO2011091153A1 (en) 2010-01-25 2011-07-28 Chdi, Inc. Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
MX2012015105A (es) * 2010-07-02 2013-05-28 Gilead Sciences Inc Inhibidores de cinasa de regulacion mediante señal de apoptosis.
CA2806734A1 (en) 2010-07-26 2012-02-09 Biomatrica, Inc. Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
EP2598660B1 (en) 2010-07-26 2017-03-15 Biomatrica, INC. Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures
US9045485B2 (en) 2010-12-16 2015-06-02 Convergence Pharmaceuticals Limited ASK 1 inhibiting pyrrolopyrimidine derivatives
BR112014004845A2 (pt) 2011-08-30 2017-04-04 Chdi Foundation Inc pelo menos uma entidade química; pelo menos um composto; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada
EP3243515B1 (en) * 2011-08-30 2019-10-16 CHDI Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
UY34573A (es) 2012-01-27 2013-06-28 Gilead Sciences Inc Inhibidor de la quinasa que regula la señal de la apoptosis
AU2015201188B2 (en) * 2012-01-27 2016-12-15 Gilead Sciences, Inc. Apoptosis signal-regulating kinase inhibitor
EP3249054A1 (en) 2012-12-20 2017-11-29 Biomatrica, INC. Formulations and methods for stabilizing pcr reagents
UY35212A (es) * 2012-12-21 2014-06-30 Gilead Sciences Inc Inhibidores de la quinasa que regula la señal de la apoptosis
US9815815B2 (en) 2013-01-10 2017-11-14 Pulmokine, Inc. Non-selective kinase inhibitors
US11491154B2 (en) 2013-04-08 2022-11-08 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
CN105491883B (zh) 2013-06-13 2018-11-02 生物马特里卡公司 细胞稳定化
US9249151B2 (en) * 2013-08-23 2016-02-02 Boehringer Ingelheim International Gmbh Bis-amido pyridines
EP3054937B1 (en) 2013-10-11 2023-07-26 Pulmokine, Inc. Spray dry formulations
WO2015070366A1 (en) * 2013-11-12 2015-05-21 Merck Sharp & Dohme Corp. Aryl linked imidazole and triazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug
CA2931615A1 (en) 2013-11-26 2015-06-04 Gilead Sciences, Inc. Therapies for treating myeloproliferative disorders
GB201321748D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
JP2017503001A (ja) 2014-01-20 2017-01-26 ギリアード サイエンシーズ， インコーポレイテッド がんを処置するための療法
WO2015187499A1 (en) 2014-06-03 2015-12-10 Gilead Sciences, Inc. Use of an ask1 inhibitor for the treatment of liver disease, optionally in combination with a loxl2 inhibitor
ES2891555T3 (es) 2014-06-10 2022-01-28 Biomatrica Inc Estabilización de trombocitos a temperaturas ambiente
EA034528B1 (ru) 2014-07-17 2020-02-17 Сиэйчдиай Фаундэйшн, Инк. Способ лечения нарушений, связанных с вич
TW201618781A (zh) 2014-08-13 2016-06-01 吉李德科學股份有限公司 治療肺高血壓之方法
KR20190035960A (ko) 2014-09-24 2019-04-03 길리애드 사이언시즈, 인코포레이티드 간 질환의 치료 방법
SG11201704738UA (en) * 2014-12-23 2017-07-28 Gilead Sciences Inc Processes for preparing ask1 inhibitors
MA41252A (fr) * 2014-12-23 2017-10-31 Gilead Sciences Inc Formes solides d'un inhibiteur d'ask 1
TW201639573A (zh) 2015-02-03 2016-11-16 吉李德科學股份有限公司 有關治療癌症之合併治療
MY199989A (en) 2015-03-04 2023-12-02 Gilead Sciences Inc Toll-like receptor modulating 4,6-diamino-pyrido[3,2-d]pyrimidine compounds
PL3896064T3 (pl) 2015-07-06 2025-09-08 Gilead Sciences, Inc. Pochodne 4,6-diamino-chinolino-3-karbonitrylu jako modulatory cot w leczeniu choroby leśniowskiego-crohna i wrzodziejącego zapalenia jelita grubego
MD3319963T2 (ro) * 2015-07-09 2020-05-31 Janssen Pharmaceutica Nv 4-Azaindoli substituiți și utilizarea lor în calitate de modulatori ai receptorului GluN2B
KR200483190Y1 (ko) 2015-09-11 2017-04-13 주식회사 엔젤악기 바로크식 운지법과 독일식 운지법의 선택 적용이 가능한 리코더 링
US20190054090A1 (en) 2015-10-01 2019-02-21 Gilead Sciences, Inc. Combination of a btk inhibitor and a checkpoint inhibitor for treating cancers
US20170107216A1 (en) 2015-10-19 2017-04-20 Incyte Corporation Heterocyclic compounds as immunomodulators
SG11201804152RA (en) 2015-11-19 2018-06-28 Incyte Corp Heterocyclic compounds as immunomodulators
KR102589056B1 (ko) 2015-12-08 2023-10-12 바이오매트리카 인코포레이티드 적혈구 침강 속도의 감소
MA44075A (fr) 2015-12-17 2021-05-19 Incyte Corp Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1
EA201891024A1 (ru) 2015-12-17 2018-12-28 Джилид Сайэнс, Инк. Соединения-ингибиторы tank-связывающей киназы
EP3828171A1 (en) 2015-12-22 2021-06-02 Incyte Corporation Heterocyclic compounds as immunomodulators
CA3016081A1 (en) 2016-03-04 2017-09-08 Gilead Sciences, Inc. Compositions and combinations of autotaxin inhibitors
EP3429997A1 (de) 2016-03-16 2019-01-23 Bayer CropScience Aktiengesellschaft N-(cyanbenzyl)-6-(cyclopropylcarbonylamino)-4-(phenyl)-pyridin-2-carboxamid-derivate und verwandte verbindungen als pestizide pflanzenschutzmittel
US20170306050A1 (en) 2016-04-08 2017-10-26 Gilead Sciences, Inc. Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
AR108396A1 (es) 2016-05-06 2018-08-15 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
TW201808902A (zh) 2016-05-26 2018-03-16 美商英塞特公司 作為免疫調節劑之雜環化合物
BR112018075737A2 (pt) 2016-06-13 2019-03-26 I-Mab anticorpo, composição, célula isolada, e, métodos para tratar câncer ou infecção em um paciente e para detectar expressão de pd-l1 em uma amostra.
AU2017281285C1 (en) 2016-06-20 2022-05-12 Incyte Corporation Heterocyclic compounds as immunomodulators
EP3484866B1 (en) 2016-07-14 2022-09-07 Incyte Corporation Heterocyclic compounds as immunomodulators
AU2017305303B2 (en) 2016-08-04 2020-05-28 Gilead Sciences, Inc. Cobicistat for use in cancer treatments
EP3504198B1 (en) 2016-08-29 2023-01-25 Incyte Corporation Heterocyclic compounds as immunomodulators
ES2826748T3 (es) 2016-09-02 2021-05-19 Gilead Sciences Inc Derivados de 4,6-diamino-pirido[3,2-d]pirimidina como moduladores de receptores de tipo Toll
AU2017318601B2 (en) 2016-09-02 2020-09-03 Gilead Sciences, Inc. Toll like receptor modulator compounds
JP2020500183A (ja) 2016-10-27 2020-01-09 プルモキネ、インコーポレイテッド 肺高血圧症の治療のための併用療法
US20180133212A1 (en) 2016-11-03 2018-05-17 Gilead Sciences, Inc. Combination of a bcl-2 inhibitor and a bromodomain inhibitor for treating cancer
CA3042398A1 (en) 2016-11-11 2018-05-17 Gilead Sciences, Inc. Methods of treating liver disease
WO2018090869A1 (zh) * 2016-11-16 2018-05-24 广东东阳光药业有限公司 酰胺衍生物及其在药物中的应用
EP3544970B1 (en) * 2016-11-22 2021-11-17 Dana-Farber Cancer Institute, Inc. Inhibitors of interleukin-1 receptor-associated kinases and uses thereof
US20180141939A1 (en) 2016-11-22 2018-05-24 Gilead Sciences, Inc. Solid forms of a bet inhibitor
IL295660A (en) 2016-12-22 2022-10-01 Incyte Corp Benzooxazole derivatives as immunomodulators
WO2018119286A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
PE20200005A1 (es) 2016-12-22 2020-01-06 Incyte Corp Derivados de tetrahidro imidazo[4,5-c]piridina como inductores de internalizacion pd-l1
US20180179179A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
EP3558989B1 (en) 2016-12-22 2021-04-14 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
WO2018133865A1 (zh) * 2017-01-22 2018-07-26 福建广生堂药业股份有限公司 Ask1抑制剂及其制备方法和应用
CA3050346C (en) * 2017-01-22 2020-07-14 Fujian Cosunter Pharmaceutical Co., Ltd. Pyridine derivative as ask1 inhibitor and preparation method and use thereof
EP3383916B1 (en) 2017-01-24 2022-02-23 I-Mab Biopharma US Limited Anti-cd73 antibodies and uses thereof
ES2926449T3 (es) 2017-02-07 2022-10-26 Biogen Ma Inc Agentes inhibidores de ASK1
CN110312720A (zh) 2017-02-24 2019-10-08 吉利德科学公司 布鲁顿氏酪氨酸激酶的抑制剂
US10314844B2 (en) 2017-02-24 2019-06-11 Gilead Sciences, Inc. Inhibitors of Bruton's tyrosine kinase
WO2018157277A1 (en) 2017-02-28 2018-09-07 Eli Lilly And Company Isoquinolin and naphthydrin compounds
US11136324B2 (en) 2017-03-03 2021-10-05 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Substituted imidazoles as apoptosis signal regulating kinase 1 inhibitors
JOP20180017A1 (ar) 2017-03-14 2019-01-30 Gilead Sciences Inc مثبط كيناز منظم لإشارة تلاشي خلايا
WO2018183122A1 (en) * 2017-03-27 2018-10-04 Sidecar Therapeutics, Inc. Apoptosis signal-regulating kinase 1 (ask 1) inhibitor compounds
AU2018246209A1 (en) 2017-03-28 2019-09-19 Gilead Sciences, Inc. Methods of treating liver disease
JOP20190221A1 (ar) * 2017-04-05 2019-09-23 Seal Rock Therapeutics Inc مركبات مثبطات كيناز منظم لإشارات الاستماتة 1 (ask1) واستخداماتها
AU2018250614A1 (en) 2017-04-12 2019-10-17 Gilead Sciences, Inc. Methods of treating liver disease
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
AU2018266911C1 (en) * 2017-05-12 2022-10-20 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
WO2018218042A1 (en) * 2017-05-25 2018-11-29 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
WO2018218044A2 (en) * 2017-05-25 2018-11-29 Enanta Pharmaceuticals Inc Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
US10450301B2 (en) 2017-05-25 2019-10-22 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
CN110770233B (zh) * 2017-06-19 2022-07-26 广东东阳光药业有限公司 稠合双环类化合物及其在药物中的应用
GB201711234D0 (en) * 2017-07-12 2017-08-23 Galapagos Nv Pyrrolopyrimidine and pyrrolopyridine derivatives
WO2019015559A1 (zh) * 2017-07-18 2019-01-24 南京圣和药业股份有限公司 作为ask抑制剂的杂环化合物及其应用
EP3284739A1 (de) 2017-07-19 2018-02-21 Bayer CropScience Aktiengesellschaft Substituierte (het)arylverbindungen als schädlingsbekämpfungsmittel
CN109400625B (zh) * 2017-08-17 2021-11-12 广东东阳光药业有限公司 稠合双环类化合物及其在药物中的应用
US10597382B2 (en) 2017-08-28 2020-03-24 Enanta Pharmaceuticals, Inc. Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
CN109456308B (zh) * 2017-09-06 2022-11-29 南京圣和药业股份有限公司 作为ask抑制剂的杂环化合物及其应用
JP2020533335A (ja) * 2017-09-08 2020-11-19 フロンセラ ユー．エス． ファーマシューティカルズ エルエルシー アポトーシスシグナル調節キナーゼ阻害剤およびその使用
CN109232538B (zh) * 2017-10-12 2020-07-24 深圳市塔吉瑞生物医药有限公司 一种1,2,4-三氮唑类化合物
CN107793400B (zh) * 2017-10-31 2020-01-31 武汉九州钰民医药科技有限公司 吡啶类化合物及其在制备治疗肝脏疾病的药物中的应用
EP3710441A1 (en) * 2017-11-17 2020-09-23 Hepagene Therapeutics, Inc. Urea derivatives as inhibitors of ask1
CN109956928B (zh) * 2017-12-14 2021-07-09 四川科伦博泰生物医药股份有限公司 吡啶类化合物、其制备方法及用途
KR102492115B1 (ko) 2017-12-20 2023-01-27 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. Sting 어댑터 단백질을 활성화하는 포스포네이트 결합을 가진 2'3' 사이클릭 다이뉴클레오티드
AU2018392213B2 (en) 2017-12-20 2021-03-04 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
EP3735404B1 (en) 2018-01-02 2023-11-29 Seal Rock Therapeutics, Inc. Ask1 inhibitor compounds and uses thereof
WO2019134680A1 (zh) * 2018-01-05 2019-07-11 广州市恒诺康医药科技有限公司 细胞凋亡信号调节激酶-1抑制剂及其应用
BR112020016466A2 (pt) 2018-02-13 2020-12-15 Gilead Sciences, Inc. Composto, composição farmacêutica, métodos para inibir pd-1, pd-l1 e/ou a interação de pd-1/pd-l1, para tratar câncer e para aprimorar a função de células-t em pacientes com hepatite b crônica (chb), e, kit para tratar ou prevenir câncer ou uma doença ou condição.
CN110294742B (zh) * 2018-03-21 2023-01-31 山东轩竹医药科技有限公司 并环类ask1抑制剂及其应用
CN110294746B (zh) * 2018-03-21 2023-01-31 山东轩竹医药科技有限公司 一种新的ask1抑制剂及其应用
KR20250067967A (ko) 2018-03-30 2025-05-15 인사이트 코포레이션 면역조절제로서 복소환형 화합물
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
EP4537902A3 (en) * 2018-04-12 2025-06-11 Terns, Inc. Tricyclic ask1 inhibitors
ES3035911T3 (en) 2018-04-19 2025-09-11 Gilead Sciences Inc Pd-1/pd-l1 inhibitors
CN110407806B (zh) * 2018-04-28 2021-08-17 深圳微芯生物科技股份有限公司 甲酰胺类化合物、其制备方法及其应用
US11008304B2 (en) * 2018-05-02 2021-05-18 Enanta Pharmaceuticals, Inc. Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
US10683289B2 (en) 2018-05-02 2020-06-16 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
WO2019211799A1 (en) 2018-05-03 2019-11-07 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
CA3098873A1 (en) 2018-05-11 2019-11-14 Phosphorex, Inc. Microparticles and nanoparticles having negative surface charges
HUE061503T2 (hu) 2018-05-11 2023-07-28 Incyte Corp Tetrahidro-imidazo[4,5-C]piridin-származékok mint PD-L1 immunmodulátorok
CN117304130A (zh) 2018-05-14 2023-12-29 吉利德科学公司 Mcl-1抑制剂
EP3814333B1 (en) * 2018-06-27 2025-03-19 Biogen MA Inc. Ask1 inhibiting agents
US10654833B2 (en) 2018-06-28 2020-05-19 Hepatikos Therapeutics, Llc ASK1 isoindolin-1-one inhibitors and methods of use thereof
AU2019301811B2 (en) 2018-07-13 2022-05-26 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
WO2020015721A1 (zh) * 2018-07-20 2020-01-23 福建广生堂药业股份有限公司 作为ask1抑制剂的晶型及其制备方法和应用
CN110818683B (zh) * 2018-08-10 2023-04-14 中国科学院上海药物研究所 2-吡啶取代脲结构小分子化合物及其合成和应用
CN111107848B (zh) * 2018-08-10 2023-05-23 江苏豪森药业集团有限公司 一种含有酰胺类衍生物的药物组合物及其制备方法和应用
MA53223A (fr) 2018-08-14 2022-04-27 Biogen Ma Inc Composés macrocycliques de pyridine en tant qu'agents inhibiteurs d'ask1
TW202021967A (zh) * 2018-08-14 2020-06-16 大陸商江蘇豪森藥業集團有限公司 凋亡信號調節激酶１抑制劑的鹽及其晶型
CN113227070A (zh) * 2018-08-14 2021-08-06 比奥根Ma公司 Ask1抑制剂
US10968199B2 (en) 2018-08-22 2021-04-06 Enanta Pharmaceuticals, Inc. Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
AR116024A1 (es) * 2018-08-29 2021-03-25 Seal Rock Therapeutics Inc Métodos de tratamiento de enfermedades neurodegenerativas
CN112384508B (zh) * 2018-09-30 2022-08-02 山东轩竹医药科技有限公司 三并环类ask1抑制剂及其应用
US11179397B2 (en) 2018-10-03 2021-11-23 Gilead Sciences, Inc. Imidazopyrimidine derivatives
JP7158577B2 (ja) 2018-10-24 2022-10-21 ギリアード サイエンシーズ， インコーポレイテッド Ｐｄ－１／ｐｄ－ｌ１阻害剤
EP3873608A1 (en) 2018-10-31 2021-09-08 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
AU2019372046B2 (en) 2018-10-31 2022-05-26 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as HPK1 inhibitors
US11345699B2 (en) 2018-11-19 2022-05-31 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
CN109608441A (zh) * 2018-12-26 2019-04-12 都创(上海)医药科技有限公司 一种ask1抑制剂的合成工艺
BR112021011762A2 (pt) 2019-01-15 2021-11-03 Gilead Sciences Inc Compostos para modulação de fxr (nr1h4)
KR102725082B1 (ko) 2019-02-19 2024-11-04 길리애드 사이언시즈, 인코포레이티드 Fxr 효능제의 고체 형태
US12318403B2 (en) 2019-03-07 2025-06-03 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′-cyclic dinucleotides and prodrugs thereof
JP7350872B2 (ja) 2019-03-07 2023-09-26 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． ３’３’－環状ジヌクレオチドおよびそのプロドラッグ
EP3935065A1 (en) 2019-03-07 2022-01-12 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
KR20240135055A (ko) 2019-03-11 2024-09-10 길리애드 사이언시즈, 인코포레이티드 화합물의 제제 및 그의 용도
WO2020198214A1 (en) 2019-03-25 2020-10-01 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI751516B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
WO2020237025A1 (en) 2019-05-23 2020-11-26 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
TWI770527B (zh) 2019-06-14 2022-07-11 美商基利科學股份有限公司 Cot 調節劑及其使用方法
WO2020255038A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
MX2021015452A (es) 2019-06-25 2022-02-11 Gilead Sciences Inc Proteinas de fusion flt3l-fc y metodos de uso.
EP4010342A1 (en) 2019-08-09 2022-06-15 Incyte Corporation Salts of a pd-1/pd-l1 inhibitor
AR119594A1 (es) 2019-08-09 2021-12-29 Gilead Sciences Inc Derivados de tienopirimidina como inhibidores acc y usos de los mismos
TWI879811B (zh) 2019-09-30 2025-04-11 美商英塞特公司 作為免疫調節劑之吡啶并[3,2-d]嘧啶化合物
ES2973832T3 (es) 2019-10-18 2024-06-24 Forty Seven Inc Terapias combinadas para el tratamiento de síndromes mielodisplásicos y leucemia mieloide aguda
AU2020374947C1 (en) 2019-10-31 2025-05-08 Forty Seven, LLC Anti-CD47 and anti-CD20 based treatment of blood cancer
PH12022551136A1 (en) 2019-11-11 2023-10-09 Incyte Corp Salts and crystalline forms of a pd-1/pd-l1 inhibitor
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
WO2021097039A1 (en) 2019-11-15 2021-05-20 Gilead Sciences, Inc. Triazole carbamate pyridyl sulfonamides as lpa receptor antagonists and uses thereof
CN111018831B (zh) * 2019-11-21 2022-05-31 中国药科大学 细胞凋亡信号调节激酶抑制剂及其应用
US20230105984A1 (en) 2019-12-23 2023-04-06 Svetlana Marukian Compositions and methods for the treatment of liver diseases and disorders
IL294032A (en) 2019-12-24 2022-08-01 Carna Biosciences Inc Compounds that regulate diacylglycerol kinase
EP4103285A2 (en) 2020-02-14 2022-12-21 Jounce Therapeutics, Inc. Antibodies and fusion proteins that bind to ccr8 and uses thereof
CA3175541A1 (en) 2020-03-30 2021-10-07 Gilead Sciences, Inc. Solid forms of (s)-6-(((1-(bicyclo[1.1.1]pentan-1-yl)-1h-1,2,3-triazol-4-yl)2-methyl-1-oxo-1,2- dihydroisoquinolin-5-yl)methyl)))amino)8-chloro-(neopentylamino)quinoline-3-carb onitrile a cot inhibitor compound
EP4613745A3 (en) 2020-04-02 2025-11-26 Gilead Sciences, Inc. Process for preparing a cot inhibitor compound
JP7564888B2 (ja) 2020-05-01 2024-10-09 ギリアード サイエンシーズ， インコーポレイテッド Ｃｄ７３阻害性２，４－ジオキソピリミジン化合物
WO2021247215A1 (en) 2020-06-03 2021-12-09 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
TWI838626B (zh) 2020-06-03 2024-04-11 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
CN113831323B (zh) * 2020-06-24 2025-08-29 武汉人福创新药物研发中心有限公司 芳杂环酰胺类化合物及其用途
CN111808079A (zh) * 2020-08-05 2020-10-23 中国药科大学 吲哚类ask1小分子抑制剂及其制备方法和应用
TW202233615A (zh) 2020-11-06 2022-09-01 美商英塞特公司 Ｐｄ—１／ｐｄ—ｌ１抑制劑之結晶形式
CN116670114A (zh) 2020-11-06 2023-08-29 因赛特公司 用于制备pd-1/pd-l1抑制剂以及其盐和结晶形式的方法
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
US12091404B2 (en) 2021-03-11 2024-09-17 Gilead Sciences, Inc. GLP-1R modulating compounds
EP4313967B1 (en) 2021-03-29 2025-11-12 Gilead Sciences, Inc. Khk inhibitors
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
TWI818538B (zh) 2021-05-11 2023-10-11 美商基利科學股份有限公司 Ｌｐａ受體拮抗劑及其用途
JP7691522B2 (ja) 2021-05-13 2025-06-11 ギリアード サイエンシーズ， インコーポレイテッド Ｌｐａ受容体アンタゴニスト及びそれらの使用
US20220389394A1 (en) 2021-05-18 2022-12-08 Gilead Sciences, Inc. METHODS OF USING FLT3L-Fc FUSION PROTEINS
TW202345826A (zh) 2021-06-04 2023-12-01 美商基利科學股份有限公司 治療nash之方法
TW202311256A (zh) 2021-06-18 2023-03-16 美商基利科學股份有限公司 用於治療ｆｘｒ誘發之搔癢之ｉｌ－３１調節劑
CN117355531A (zh) 2021-06-23 2024-01-05 吉利德科学公司 二酰基甘油激酶调节化合物
CA3220923A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
EP4359413A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CN117377671A (zh) 2021-06-23 2024-01-09 吉利德科学公司 二酰基甘油激酶调节化合物
JP2024539252A (ja) 2021-10-28 2024-10-28 ギリアード サイエンシーズ， インコーポレイテッド ピリジジン－３（２ｈ）－オン誘導体
PE20241186A1 (es) 2021-10-29 2024-06-03 Gilead Sciences Inc Compuestos de cd73
US20230220106A1 (en) 2021-12-08 2023-07-13 Dragonfly Therapeutics, Inc. Antibodies targeting 5t4 and uses thereof
KR20240115978A (ko) 2021-12-08 2024-07-26 길리애드 사이언시즈, 인코포레이티드 Lpa 수용체 길항제 및 이의 용도
WO2023107956A1 (en) 2021-12-08 2023-06-15 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and 5t4
JP2024546851A (ja) 2021-12-22 2024-12-26 ギリアード サイエンシーズ， インコーポレイテッド Ｉｋａｒｏｓジンクフィンガーファミリー分解剤及びその使用
CA3237577A1 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
PL4245756T3 (pl) 2022-03-17 2025-02-17 Gilead Sciences, Inc. Środki degradujące palec cynkowy z rodziny ikaros i ich zastosowania
US20230355796A1 (en) 2022-03-24 2023-11-09 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TWI876305B (zh) 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
CA3249472A1 (en) 2022-04-21 2023-10-26 Gilead Sciences, Inc. KIRSTEN G12D RAT SARCOMA VIRUS MODULATOR COMPOUNDS
AU2023298558A1 (en) 2022-07-01 2024-12-19 Gilead Sciences, Inc. Cd73 compounds
WO2024059216A2 (en) * 2022-09-15 2024-03-21 Vanderbilt University 6,6 southwestern core compounds as mglu5 negative allosteric modulators and methods of making and using the same
WO2024059212A2 (en) * 2022-09-15 2024-03-21 Vanderbilt University 6,6 western core compounds as mglu5 negative allosteric modulators and methods of making and using the same
WO2024064668A1 (en) 2022-09-21 2024-03-28 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
CN120225509A (zh) 2022-12-22 2025-06-27 吉利德科学公司 Prmt5抑制剂及其用途
CN116874468B (zh) * 2022-12-24 2025-08-29 江西中医药大学 具有2-吡啶取代甲酰胺结构的小分子化合物的合成和应用
CN120882725A (zh) 2023-04-11 2025-10-31 吉利德科学公司 Kras调节化合物
KR20250175331A (ko) 2023-04-21 2025-12-16 길리애드 사이언시즈, 인코포레이티드 Prmt5 억제제 및 이의 용도
AU2024306338A1 (en) 2023-06-30 2026-01-08 Gilead Sciences, Inc. Kras modulating compounds
WO2025024811A1 (en) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Parp7 inhibitors
US20250066328A1 (en) 2023-07-26 2025-02-27 Gilead Sciences, Inc. Parp7 inhibitors
US20250101042A1 (en) 2023-09-08 2025-03-27 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250154172A1 (en) 2023-11-03 2025-05-15 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025245003A1 (en) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
CA1121825A (en) 1978-04-11 1982-04-13 Franco Bolasco 2-(2-thenoylthio)-propionylglycine: method for its preparation and pharmaceutical formulations containing said compound
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
WO1998034946A1 (en) 1997-02-12 1998-08-13 Massachusetts Institute Of Technology Daxx, a novel fas-binding protein that activates jnk and apoptosis
AUPP285898A0 (en) * 1998-04-07 1998-04-30 Fujisawa Pharmaceutical Co., Ltd. Amido derivatives
DK1144600T3 (da) 1999-03-19 2008-11-24 Aventis Pharma Inc Akt-3-nukleinsyre, polypeptider og anvendelser deraf
US6881555B2 (en) 1999-03-19 2005-04-19 Aventis Pharmaceuticals Inc. AKT nucleic acids, polypeptides, and uses thereof
WO2001068585A1 (en) * 2000-03-14 2001-09-20 Fujisawa Pharmaceutical Co., Ltd. Novel amide compounds
JPWO2002038179A1 (ja) * 2000-11-10 2004-03-11 キッセイ薬品工業株式会社 小胞体ストレス関連疾患の予防又は治療剤
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US20070237770A1 (en) 2001-11-30 2007-10-11 Albert Lai Novel compositions and methods in cancer
TW200400963A (en) 2002-05-21 2004-01-16 Wyeth Corp R-enantiomers of pyranoindole derivatives and the use thereof for the treatment of hepatitis C virus infection or disease
TW200400818A (en) 2002-05-21 2004-01-16 Wyeth Corp Method for the use of pyranoindole derivatives to treat infection with hepatitis C virus
JPWO2005009470A1 (ja) 2003-07-28 2006-09-28 財団法人大阪産業振興機構 Ａｓｋ１阻害剤を有効成分とする心不全治療薬およびそのスクリーニング方法
TW200526626A (en) 2003-09-13 2005-08-16 Astrazeneca Ab Chemical compounds
GB0324551D0 (en) 2003-10-21 2003-11-26 Karobio Ab Novel compounds
US7078064B2 (en) 2003-12-03 2006-07-18 George Zabrecky Compositions and methods useful for treating and preventing chronic liver disease, chronic HCV infection and non-alcoholic steatohepatitis
JP2008514635A (ja) 2004-09-27 2008-05-08 コーザン バイオサイエンシス インコーポレイテッド 特異的キナーゼ阻害剤
AU2005304393B2 (en) * 2004-11-10 2012-09-27 Synta Pharmaceuticals Corp. IL-12 modulatory compounds
JP2008524233A (ja) 2004-12-16 2008-07-10 バーテックス ファーマシューティカルズ インコーポレイテッド 炎症性疾患、増殖性疾患および免疫介在性疾患の治療のためのｔｅｃファミリータンパク質キナーゼのインヒビターとして有用なピリド−２−オン
EP1677113A1 (en) 2004-12-29 2006-07-05 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Method for the identification of protein-protein interactions in disease related protein networks
US20070276050A1 (en) 2006-02-27 2007-11-29 Gilead Sciences, Inc. Methods for identifying ASK1 inhibitors useful for preventing and/or treating cardiovascular diseases
US20080021217A1 (en) 2006-07-20 2008-01-24 Allen Borchardt Heterocyclic inhibitors of rho kinase
EP2058309A4 (en) * 2006-08-04 2010-12-22 Takeda Pharmaceutical CONDENSED HETEROCYCLIC COMPOUND
WO2008042867A2 (en) 2006-09-29 2008-04-10 Emiliem Inc. Modulators of multiple kinases
AU2007333106A1 (en) 2006-12-08 2008-06-19 Asuragen, Inc. miR-20 regulated genes and pathways as targets for therapeutic intervention
WO2009011850A2 (en) 2007-07-16 2009-01-22 Abbott Laboratories Novel therapeutic compounds
MX2010002312A (es) 2007-08-31 2010-03-18 Merck Serono Sa Compuestos de triazolopiridina y su uso como inhibidores de cinasa reguladora de señal de apoptosis.
CA2708300A1 (en) 2007-12-11 2009-06-18 Schering Corporation Gamma secretase modulators
WO2009123986A1 (en) 2008-03-31 2009-10-08 Takeda Pharmaceutical Company Limited Apoptosis signal-regulating kinase 1 inhibitors
US8178555B2 (en) 2008-06-24 2012-05-15 Takeda Pharmaceutical Company Limited Apoptosis signal-regulating kinase 1 inhibitors
WO2010045470A2 (en) 2008-10-15 2010-04-22 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of hepatic disorders
US20110294693A1 (en) 2008-11-17 2011-12-01 The George Washington University Compositions and Methods for Identifying Autism Spectrum Disorders
PA8854101A1 (es) 2008-12-18 2010-07-27 Ortho Mcneil Janssen Pharm Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa
JP2012521760A (ja) 2009-03-27 2012-09-20 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたアポトーシスシグナル調節キナーゼ１（ＡＳＫ１）遺伝子発現のＲＮＡ干渉媒介性阻害
TWI598347B (zh) 2009-07-13 2017-09-11 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
CN102834393B (zh) 2010-02-03 2015-07-22 武田药品工业株式会社 细胞凋亡信号调节激酶1抑制剂
EP2534145A4 (en) 2010-02-08 2013-09-11 Kinagen Inc THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING THE INHIBITION OF ALLOSTERIC KINASE
WO2011119894A2 (en) 2010-03-24 2011-09-29 Kinagen, Inc Heterocyclic compounds useful for kinase inhibition
MX2012015105A (es) 2010-07-02 2013-05-28 Gilead Sciences Inc Inhibidores de cinasa de regulacion mediante señal de apoptosis.
TW201300380A (zh) 2010-10-19 2013-01-01 Comentis Inc 抑制β－分泌酶活性之噁二唑化合物及其使用方法
US20130236441A1 (en) 2010-11-18 2013-09-12 University Of Delaware Methods of treating and preventing thrombotic diseases using ask1 inhibitors
US9045485B2 (en) 2010-12-16 2015-06-02 Convergence Pharmaceuticals Limited ASK 1 inhibiting pyrrolopyrimidine derivatives
CN103492590A (zh) 2011-02-22 2014-01-01 卡里斯生命科学卢森堡控股有限责任公司 循环生物标志物
JP2014526032A (ja) 2011-06-07 2014-10-02 カリス ライフ サイエンシズ ルクセンブルク ホールディングス エス．アー．エール．エル． 癌に対する循環バイオマーカー
TW201837023A (zh) 2011-07-01 2018-10-16 美商基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
PL3329919T3 (pl) 2011-11-11 2020-05-18 Gilead Apollo, Llc Inhibitory ACC i ich zastosowania
UY34573A (es) 2012-01-27 2013-06-28 Gilead Sciences Inc Inhibidor de la quinasa que regula la señal de la apoptosis
UY35212A (es) 2012-12-21 2014-06-30 Gilead Sciences Inc Inhibidores de la quinasa que regula la señal de la apoptosis
EA201690973A1 (ru) 2013-12-20 2016-11-30 Джилид Сайэнс, Инк. Ингибиторы киназ, регулирующих сигнал к апоптозу
CN103896990B (zh) 2014-03-12 2017-02-08 石家庄诚志永华显示材料有限公司 有机电致发光材料及其应用
WO2015187499A1 (en) 2014-06-03 2015-12-10 Gilead Sciences, Inc. Use of an ask1 inhibitor for the treatment of liver disease, optionally in combination with a loxl2 inhibitor
KR20190035960A (ko) 2014-09-24 2019-04-03 길리애드 사이언시즈, 인코포레이티드 간 질환의 치료 방법
EP3034499A1 (en) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Novel FXR (NR1H4) modulating compounds
SG11201704738UA (en) 2014-12-23 2017-07-28 Gilead Sciences Inc Processes for preparing ask1 inhibitors
MA41252A (fr) 2014-12-23 2017-10-31 Gilead Sciences Inc Formes solides d'un inhibiteur d'ask 1
AU2016205138A1 (en) 2015-01-09 2017-07-13 Gilead Apollo, Llc ACC inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease
US10183951B2 (en) 2016-03-02 2019-01-22 Gilead Apollo, Llc Solid forms of a thienopyrimidinedione ACC inhibitor and methods for production thereof
CA3252823A1 (en) 2016-06-13 2025-02-25 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
KR102269305B1 (ko) 2016-06-13 2021-06-25 길리애드 사이언시즈, 인코포레이티드 Fxr (nr1h4) 조정 화합물
CA3042398A1 (en) 2016-11-11 2018-05-17 Gilead Sciences, Inc. Methods of treating liver disease
JOP20180017A1 (ar) 2017-03-14 2019-01-30 Gilead Sciences Inc مثبط كيناز منظم لإشارة تلاشي خلايا
KR20220119520A (ko) 2017-03-28 2022-08-29 길리애드 사이언시즈, 인코포레이티드 간 질환을 치료하기 위한 치료 조합물
AU2018246209A1 (en) 2017-03-28 2019-09-19 Gilead Sciences, Inc. Methods of treating liver disease
AU2018250614A1 (en) 2017-04-12 2019-10-17 Gilead Sciences, Inc. Methods of treating liver disease
CA3077273A1 (en) 2017-10-06 2019-04-11 Gilead Sciences, Inc. Combination therapy comprising an acc inhibitor

Also Published As

Publication number Publication date
PL3363797T3 (pl) 2021-06-28
NZ597533A (en) 2014-03-28
EP2933252A1 (en) 2015-10-21
TW201113271A (en) 2011-04-16
WO2011008709A1 (en) 2011-01-20
KR20170081722A (ko) 2017-07-12
CA2767894A1 (en) 2011-01-20
JP2012532931A (ja) 2012-12-20
PL2454250T3 (pl) 2015-08-31
HK1170482A1 (en) 2013-03-01
HRP20150185T1 (hr) 2015-04-10
MX2012000708A (es) 2012-03-21
JP5745721B2 (ja) 2015-07-08
CY1119889T1 (el) 2018-06-27
RS53951B1 (sr) 2015-08-31
PT3363797T (pt) 2021-02-23
EP3363797A8 (en) 2021-04-28
TW201604189A (zh) 2016-02-01
TWI491606B (zh) 2015-07-11
USRE48711E1 (en) 2021-08-31
EP3363797B1 (en) 2020-12-02
US20130012521A1 (en) 2013-01-10
JP2018184464A (ja) 2018-11-22
HK1216426A1 (en) 2016-11-11
US8378108B2 (en) 2013-02-19
US20170196844A1 (en) 2017-07-13
HRP20180413T1 (hr) 2018-04-20
CN102482257B (zh) 2016-01-20
JP2017071647A (ja) 2017-04-13
KR20180077338A (ko) 2018-07-06
ES2662397T3 (es) 2018-04-06
US8598360B2 (en) 2013-12-03
ES2854710T3 (es) 2021-09-22
TW201737914A (zh) 2017-11-01
HUE038529T2 (hu) 2018-10-29
US20160130251A1 (en) 2016-05-12
EP2933252B1 (en) 2018-01-03
US9067933B2 (en) 2015-06-30
UY32786A (es) 2011-02-28
EP2454250A1 (en) 2012-05-23
US20110009410A1 (en) 2011-01-13
TWI598347B (zh) 2017-09-11
CN102482257A (zh) 2012-05-30
ES2854710T8 (es) 2022-02-11
SI2933252T1 (en) 2018-02-28
SMT201500090B (it) 2015-05-05
SI3363797T1 (sl) 2021-03-31
AU2010273597B2 (en) 2015-07-09
JP2015098500A (ja) 2015-05-28
TWI625121B (zh) 2018-06-01
ME02104B (me) 2016-06-20
EP3363797A1 (en) 2018-08-22
AU2010273597A1 (en) 2012-02-02
SMT201800172T1 (it) 2018-05-02
EP3858824A1 (en) 2021-08-04
LT2933252T (lt) 2018-03-12
PL2933252T3 (pl) 2018-06-29
KR20120034735A (ko) 2012-04-12
EP2454250B1 (en) 2015-01-14
DK2933252T3 (en) 2018-04-16
EP3363797B8 (en) 2021-03-03
US20140018370A1 (en) 2014-01-16
US20130035339A1 (en) 2013-02-07
SI2454250T1 (sl) 2015-04-30
US9586932B2 (en) 2017-03-07
CA2767894C (en) 2015-09-15
KR101755524B1 (ko) 2017-08-02
PT2933252T (pt) 2018-03-15
BR112012000894A2 (pt) 2016-02-23
US8552196B2 (en) 2013-10-08
PT2454250E (pt) 2015-04-09
NO2933252T3 (es) 2018-06-02
RS56981B1 (sr) 2018-05-31
DK2454250T3 (en) 2015-04-20
ES2533796T3 (es) 2015-04-14

Similar Documents

Publication Publication Date Title
AR077564A1 (es) Inhibidores de quinasa que regulan la senal de apoptosis
PE20212247A1 (es) Compuestos de 3-((3-aminofenil)amino)piperidina-2,6-diona sustituida, composiciones de estos y metodos de tratamiento con estos
PE20240879A1 (es) Inhibidor sos1 y uso del mismo
AR093184A1 (es) Compuesto de pirimidina sustituida como inhibidor de quinurenina-3-monooxigenasa y composicion farmaceutica que lo comprenden
AR086829A1 (es) Compuestos heterociclicos fusionados como moduladores del canal ionico
AR105640A1 (es) Derivados heterobicíclicos microbicidas
CY1124537T1 (el) Παραγωγο πυριδονης που εχει τετραϋδροπυρανυλ μεθυλ ομαδα
AR101586A1 (es) Derivados heterocíclicos con sustituyentes que contienen azufre activos como plaguicidas
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
AR103265A1 (es) Compuestos de azolina sustituidos con un sistema de anillos condensado
PE20181144A1 (es) Derivados de heteroarilo como inhibidores de parp
PH12017501652A1 (en) Kv1.3 inhibitors and their medical application
AR081045A1 (es) Derivados de quinazolinediona como moduladores trpa1
AR104307A1 (es) Tetralinas de ácido 3-espirocíclico-6-hidroxámico como inhibidores de hdac
AR071652A1 (es) Derivados 2- fenil-piridina substituidos
AR105893A1 (es) Derivados del anillo (hetero) aromático sustituidos con carboxi como inhibidores de xantina oxidasa y del transportador 1 del anión urato
BR112016019462B8 (pt) Compostos heterocïclicos tricïclicos como inibidores de fosfoinosotida 3-cinase
AR107030A1 (es) Inhibidores aza-bencimidazol de pad4
AR103266A1 (es) Compuestos cíclicos sustituidos con un sistema de anillos condensado para combatir plagas de invertebrados
PE20190979A1 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
AR048789A1 (es) Derivados de oxazol y sus composiciones como moduladores de receptor activado de proliferador de peroxisoma (ppar)
AR109964A1 (es) Derivados de aril-sulfonamidas como bloqueadores del canal de sodio
AR083501A1 (es) 1-(heterociclo carbonil)piperidinas
AR075474A1 (es) Inhibidores de cyp17 de decahidro-1h-indenoquinolinona y decahidro-3h-ciclopentafenantridinona, composiciones farmaceuticas y metodos de tratamiento
AR103582A1 (es) Ciclopropabenzofuranil-piridopirazindionas

Legal Events

Date Code Title Description
FG Grant, registration